Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 158, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2020.103209
Keywords
Ovarian cancer; Upfront therapy; PARP inhibitors; Antiangiogenics; Maintenance therapy; Chemotherapy
Categories
Funding
- Sociedad Espanola de Oncologia Medica (SEOM)
Ask authors/readers for more resources
Despite attempts to improve outcomes of advanced ovarian cancer patients with different strategies over the past few decades, the landscape of first-line treatment for AOC remained unchanged until the last three years.
Despite optimal first-line treatment based on debulking surgery and platinum-paclitaxel chemotherapy, most of the patients with advanced ovarian cancer (AOC) will eventually relapse. Over the last decades, different strategies have been assessed to improve AOC patients' outcomes in the front-line treatment. However, first line treatment landscape of AOC had not undergone major changes until the last three years. In the present review, we will navigate through the different therapeutic approaches developed in first-line AOC which range from variations in dose/administration via of conventional carboplatin-based chemotherapy to the incorporation of anti-angiogenic agents and PARP inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available